US Patent

US8906938 — C5aR antagonists

Composition of Matter · Assigned to Chemocentryx Inc · Expires 2034-01-06 · 8y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds that are modulators of the C5a receptor, specifically substituted piperidines useful in treating diseases involving C5a receptor activation.

USPTO Abstract

Compounds are provided that are modulators of the C5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of C5a receptors.

Drugs covered by this patent

Patent Metadata

Patent number
US8906938
Jurisdiction
US
Classification
Composition of Matter
Expires
2034-01-06
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Chemocentryx Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.